Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Determining the probability of an important difference in bioavailability

B E Rodda, R L Davis

    Clinical Pharmacology and Therapeutics
    |August 1, 1980
    PubMed
    Summary
    This summary is machine-generated.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Generation of the iPSC line FINi002-A from a male Parkinson's disease patient carrying compound heterozygous mutations in the PRKN gene.

    Stem cell research·2023
    Same author

    A Longitudinal HbA1c Model Elucidates Genes Linked to Disease Progression on Metformin.

    Clinical pharmacology and therapeutics·2016
    Same author

    Transcriptome sequencing implicates dorsal striatum-specific gene network, immune response and energy metabolism pathways in bipolar disorder.

    Molecular psychiatry·2016
    Same author

    Novel, primate-specific PDE10A isoform highlights gene expression complexity in human striatum with implications on the molecular pathology of bipolar disorder.

    Translational psychiatry·2016
    Same author

    Gravitational Waves and the Cosmic Microwave Background.

    Annals of the New York Academy of Sciences·2015
    Same author

    A novel OPA1 mutation causing variable age of onset autosomal dominant optic atrophy plus in an Australian family.

    Journal of neurology·2015

    This study introduces a new method to assess drug bioavailability, focusing on clinical significance over statistical significance. It helps determine the probability of a meaningful difference between formulations, even with non-significant results.

    Area of Science:

    • Pharmacokinetics
    • Biopharmaceutics
    • Statistical analysis in drug development

    Background:

    • Traditional bioavailability studies often rely on statistical significance, which may not reflect clinical relevance.
    • Ambiguous results in bioavailability studies (large non-significant or small significant differences) pose challenges for clinical interpretation.

    Purpose of the Study:

    • To develop a methodology for calculating the probability of a clinically important difference in bioavailability between drug formulations.
    • To move beyond traditional hypothesis testing and provide a more definitive statement on the likelihood of meaningful bioavailability variations.

    Main Methods:

    • Proposed a novel statistical methodology to compute the probability of a clinically significant bioavailability difference.
    • Applied the method to a case study involving two drug formulations with a 2% observed difference.

    Related Experiment Videos

    Main Results:

    • The new methodology allows for direct probability statements about clinically meaningful differences.
    • In an example case, the analysis indicated approximately 5:1 odds against a 20% bioavailability difference, despite a non-significant 2% observed difference.

    Conclusions:

    • The proposed approach offers a more robust assessment of bioavailability differences by focusing on clinical significance.
    • This methodology provides clearer insights into the likelihood of meaningful variations between drug products, enhancing decision-making in drug development.